heart failure | versus placebo or control No demonstrated result for efficacy ibopamine inferior to placebo in terms of Total mortality in PRIME II, 1997 ibopamine inferior to placebo in terms of Sudden death in PRIME II, 1997 | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PRIME II, 1997 | ibopamine vs placebo | | Total mortality 1.20 [1.02; 1.42] Sudden death 1.50 [1.04; 2.15] | Cardiac death 0.71 [0.37; 1.38] Transplantation 0.95 [0.53; 1.72] |
Trial | Treatments | Patients | Method |
---|
PRIME II, 1997 | oral ibopamine 100 mg three times daily (n=953) vs. placebo (n=953) | patients with heart failure NYHA III-IV | double blind Parallel groups Sample size: 953/953 Primary endpoint: Total mortality FU duration: mean 11.4 months |
|